Life Scientist > Lab Technology

Dynamic Hearing signs agreement with House Ear Institute

23 November, 2005 by Ruth Beran

Melbourne-based biomedical company Dynamic Hearing has signed an agreement with the House Ear Institute (HEI) to develop and commercialise the US-based non-profit organisation's patented feedback cancellation technology for use in hearing aids and auditory implants.


AusBiotech, South Korea sign agreement

23 November, 2005 by Iain Scott

AusBiotech and its South Korean equivalent, the Bioindustry Association of Korea (BAK), have signed an agreement that they hope will lead to a stronger relationship between the two countries' biotech industries.


BioProspect to raise AUD$1.95m

22 November, 2005 by Helen Schuller

Brisbane natural pesticide developer BioProspect (ASX:BPO) is planning to raise AUD$1.95 million via a share placement and rights issue.


TetraQ forms strategic alliance with US company

22 November, 2005 by Ruth Beran

University of Queensland based contract research organisation TetraQ has formed a strategic alliance with Californian-based regulatory and product development consulting firm Ground Zero Pharmaceuticals (GZP).


CyGenics plans Cordlife listing in Asia

22 November, 2005 by Helen Schuller

Cell therapy company CyGenics (ASX:CYN) plans to investigate the possible listing of its tissue banking business, predominantly held under its subsidiary, CordLife, on a yet to be determined key Asian stock exchange.


Bridges, Brumby given AusBiotech honours

21 November, 2005 by Helen Schuller

The AusBiotech 2005 'Linking the Region' National Conference kicked off in Perth last night with the presentation of the chairman's Industry Medal to Peptech (ASX: PTD) executive chairman Mel Bridges and Victorian Innovation Minister John Brumby in recognition of outstanding contributions to the biotechnology industry.


International study to use Gribbles testing

21 November, 2005 by Ruth Beran

Gribbles Molecular Science (GMS), the biotechnology and molecular diagnostic division of Healthscope (ASX:HSP), has been selected to conduct genomic testing in an international collaborative study into depression.


The ASX: A haven for foreign biotech companies?

21 November, 2005 by Helen Schuller

The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.


Australian biotech: Opportunity for growth

17 November, 2005 by Ruth Beran

Ruth Beran looks at some of the many highlights expected at the 2005 AusBiotech national conference in Perth, which kicks off on Monday.


INTERVIEW: The jewel in India's biotech crown

17 November, 2005 by Melissa Trudinger

Kiran Mazumdar-Shaw spoke with Melissa Trudinger about ways in which India and Australia can work together in biotech.


INTERVIEW: New AusBiotech head stakes her position

17 November, 2005 by Ruth Beran

Since she took the top job at AusBiotech on the eve of the BIO conference earlier this year, Anna Lavelle has done a lot of listening. Now she's ready to talk -- about her role and her vision for the organisation.


Hatchtech awarded $2.4m grant

17 November, 2005 by Ruth Beran

Unlisted Melbourne biotech Hatchtech has been awarded a AUD$2.4 million AusIndustry Commercial Ready grant to support its head lice treatment R&D program.


Tissue Therapies raises $1.6m, announces SPP

17 November, 2005 by Ruth Beran

Brisbane biotech Tissue Therapies (ASX:TIS) has completed a placement to investors, raising AUD$1.6 million before costs.


Premier Bionics division gets Hong Kong order

17 November, 2005 by Helen Schuller

Medic Vision, a wholly owned subsidiary of Premier Bionics (ASX:PBI), has received an initial order for its surgical simulation products worth almost $460,000 from a hospital in Hong Kong.


Cryptome to acquire HealthLinx

17 November, 2005 by Helen Schuller

Melbourne biopharma Cryptome Pharmaceuticals (ASX:CRP) has entered a non-binding terms sheet to acquire HealthLinx, a privately-held diagnostics specialist with lead candidates targeting ovarian cancer and complications in pregnancy.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd